The UK's 100,000 MS sufferers could be offered new hope after scientists discovered that a leukaemia drug can be used to reverse the effects of the disease.
The University of Cambridge study found alemtuzumab can stop relapsing/remitting MS advancing in patients in the early stages of the condition.
MS causes the immune system to attack the protective coating around nerve fibres which prevents messages being transmitted between the brain and other parts of the body. Symptoms include loss of physical skills, sensation, vision, bladder control and intellectual abilities.
Researchers believe alemtuzumab may allow damaged brain tissue to repair and restore lost nerve function.
However, side-effects include developing other autoimmune diseases because the immune system gradually recovers from alemtuzumab exposure.